These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20157167)

  • 21. [Advantages in diagnostic and treatment of MS].
    Hjaltason H
    Laeknabladid; 2008 May; 94(5):359. PubMed ID: 18460730
    [No Abstract]   [Full Text] [Related]  

  • 22. Polypharmacy in multiple sclerosis.
    Myers LW; Phillips JT
    Epilepsy Res Suppl; 1996; 11():181-95. PubMed ID: 9294736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis.
    Khan O; Shen Y; Bao F; Caon C; Tselis A; Latif Z; Zak I
    J Neuroimaging; 2008 Jul; 18(3):314-9. PubMed ID: 18304034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of brain tumors associated with exposure to exogenous female sex hormones.
    Wigertz A; Lönn S; Mathiesen T; Ahlbom A; Hall P; Feychting M;
    Am J Epidemiol; 2006 Oct; 164(7):629-36. PubMed ID: 16835295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Natalizumab in multiple sclerosis: unclear patient benefits].
    Schipper JP
    Ned Tijdschr Geneeskd; 2007 Apr; 151(15):852-5. PubMed ID: 17472115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Suspected multiple sclerosis].
    Pellkofer H; Hohlfeld R
    MMW Fortschr Med; 2006 Mar; 148(13):63-4. PubMed ID: 16642711
    [No Abstract]   [Full Text] [Related]  

  • 28. Natalizumab, multiple sclerosis, and primary central nervous system lymphoma: enigma, wrapped in mystery, enclosed in conundrum.
    Ransohoff RM
    Ann Neurol; 2009 Sep; 66(3):259-61. PubMed ID: 19798722
    [No Abstract]   [Full Text] [Related]  

  • 29. Segregation analysis of cancer in families of glioma patients.
    de Andrade M; Barnholtz JS; Amos CI; Adatto P; Spencer C; Bondy ML
    Genet Epidemiol; 2001 Feb; 20(2):258-70. PubMed ID: 11180451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Agricultural pesticide use and risk of glioma in Nebraska, United States.
    Lee WJ; Colt JS; Heineman EF; McComb R; Weisenburger DD; Lijinsky W; Ward MH
    Occup Environ Med; 2005 Nov; 62(11):786-92. PubMed ID: 16234405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived.
    Weissert R
    Expert Rev Neurother; 2006 Nov; 6(11):1587-90. PubMed ID: 17144774
    [No Abstract]   [Full Text] [Related]  

  • 32. Interferons and multiple sclerosis: is it plausible that beta-IFN treatment could influence the risk of cancer among MS patients?
    Kingwell E; Tremlett H
    Expert Rev Neurother; 2009 Sep; 9(9):1263-5. PubMed ID: 19769440
    [No Abstract]   [Full Text] [Related]  

  • 33. [Contralateral pain-flexor reflex in damage to the ventrocaudal and lateral thalamus].
    Sayk J; Schröter P; Kmietzyk HJ
    Nervenarzt; 1983 Oct; 54(10):513-20. PubMed ID: 6316181
    [No Abstract]   [Full Text] [Related]  

  • 34. Daclizumab treatment for multiple sclerosis.
    Kim SE
    Pharmacotherapy; 2009 Feb; 29(2):227-35. PubMed ID: 19170591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.
    Balcer LJ; Galetta SL; Calabresi PA; Confavreux C; Giovannoni G; Havrdova E; Hutchinson M; Kappos L; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA
    Neurology; 2007 Apr; 68(16):1299-304. PubMed ID: 17438220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 'Time is brain' also in multiple sclerosis.
    Freedman MS
    Mult Scler; 2009 Oct; 15(10):1133-4. PubMed ID: 19808740
    [No Abstract]   [Full Text] [Related]  

  • 37. Severe cutaneous Candida infection during natalizumab therapy in multiple sclerosis.
    Gutwinski S; Erbe S; Münch C; Janke O; Müller U; Haas J
    Neurology; 2010 Feb; 74(6):521-3. PubMed ID: 20142621
    [No Abstract]   [Full Text] [Related]  

  • 38. Balancing risk and reward: the question of natalizumab.
    Hauser SL; Johnston SC
    Ann Neurol; 2009 Sep; 66(3):A7-8. PubMed ID: 19810091
    [No Abstract]   [Full Text] [Related]  

  • 39. [Methodologic and ethical implications of immunosuppressive therapy in multiple sclerosis].
    Szobor A
    Orv Hetil; 1984 Mar; 125(11):673. PubMed ID: 6700975
    [No Abstract]   [Full Text] [Related]  

  • 40. Natalizumab: infections, hypersensitivity, etc.
    Prescrire Int; 2011 Dec; 20(122):297. PubMed ID: 22232812
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.